GlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new genomics research lab at the University of California.
Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.
Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.
Insys has declared bankruptcy, hard on the heels of its agreement last week to a $225 million payment to settle charges it bribed doctors to prescribe opioid painkillers.
Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its third pipeline-boosting deal in a little over four months.